Gonadotropin-releasing hormone antagonists: Impact of IVF practice and potential non-assisted reproductive technology applications

Current Opinion in Obstetrics and Gynecology

Volumn 15, Issue 3, 2003, Pages 259-264

  Tarlatzis, Basil C ^a,b   Bili, Helen N ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b Geniki Kliniki   (Greece)

Author keywords

Endometriosis; GnRH antagonists; Myomas; Ovarian stimulation; Poor responders

Indexed keywords

CETRORELIX; CHORIONIC GONADOTROPIN; CLOMIFENE CITRATE; GANIRELIX; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; GONADORELIN RECEPTOR; GONADOTROPIN; HUMAN MENOPAUSAL GONADOTROPIN; LUTEINIZING HORMONE; RECOMBINANT FOLLITROPIN;

ARTIFICIAL INSEMINATION; BREAST CANCER; CLINICAL PRACTICE; CLINICAL PROTOCOL; CLINICAL TRIAL; DOSE CALCULATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; EMBRYO TRANSFER; ENDOMETRIOSIS; ENDOMETRIUM; ESTROGEN SYNTHESIS; FERTILIZATION IN VITRO; FOLLICULAR PHASE; GONADOTROPIN RELEASE; GYNECOLOGIC CANCER; HUMAN; INFERTILITY; INFERTILITY THERAPY; INTRACYTOPLASMIC SPERM INJECTION; LEIOMYOMA; LOW DRUG DOSE; LUTEAL PHASE; LUTEINIZING HORMONE RELEASE; MENSTRUAL CYCLE; NONHUMAN; OOCYTE MATURATION; OVARY FOLLICLE; OVARY FUNCTION; PRECOCIOUS PUBERTY; PREGNANCY; PREGNANCY RATE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CARCINOMA; PROSTATE HYPERTROPHY; REVIEW; SIDE EFFECT; TREATMENT PLANNING; TUMOR VOLUME;

FEMALE; FERTILITY AGENTS, FEMALE; FERTILIZATION IN VITRO; GONADOTROPIN-RELEASING HORMONE; HORMONE ANTAGONISTS; HUMANS; OVULATION INDUCTION; PREGNANCY;

EID: 0037944261     PISSN: 1040872X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001703-200306000-00009     Document Type: Review

References (58)

1. Stanger JD, Yovich JL. Reduced in-vitro fertilization of human oocytes from patients with raised basal luteinizing hormone levels during the follicular phase. Br J Obstet Gynecol 1985; 92:385-393.
2. Van Uem JFHM, Garcia JE, Liu HC, et al. Clinical aspects with regards to the occurrence of an endogenous luteinizing hormone surge in gonadotrophin-induced normal menstrual cycles. J In Vitro Fertil Embryo Transfer 1986; 3:345-349.
3. Testart J, Lefevre B, Gougeon A. Effects of gonadotrophin-releasing hormone agonists (GnRHa) on follicle and oocyte quality. Hum Reprod 1993; 8:511-518.
4. Dhont M, Onghena A, Coetsier T, et al. Prospective randomized study of clomiphene citrate and gonadotrophins versus goserelin and gonadotrophins for follicular stimulation in assisted reproduction. Hum Reprod 1995; 10:791-796.
5. Fauser BCJM, Devroey P, Yen SSC, et al. Minimal ovarian stimulation for IVF: appraisal of potential benefits and drawbacks. Hum Reprod 1999; 14:2681-2686.
6. Smitz J, Ron-El R, Tarlatzis BC. The use of gonadotrophin releasing hormone agonists for in vitro fertilization and other assisted procreation techniques: experience from three centers. Hum Reprod 1992; 7:49-66.
7. Karten MJ, Hoeger CA, Hooh WA, et al. The development of safer antagonists: strategy and status. In: Bouchard P, Haour F, Franchimont P, Schatz B, editors. Recent progress on GnRH and gonadal peptides. Paris: Elsevier, Session II; 1990. pp. 147-158.
8. Diedrich K, Diedrich C, Santos E, et al. Suppression of the endogenous luteinizing hormone surge by the gonadotropin-releasing hormone antagonist Cetrorelix during ovarian stimulation. Hum Reprod 1994; 9:99-91.
9. Leroy I, Frydman R, d'Acremont ME, et al. A single injection of a GnRH antagonist (Cetrorelix) postpones the luteinizing hormone (LH) surge: further evidence for the role of GnRH during the LH surge. Fertil Steril 1994; 62:461-467.
10. Rivier JE, Porter J, Rivier CL. New effective GnRH antagonists with minimal potency for histamine release in vitro. J Med Chem 1986; 29:1846-1851.
11. Olivennes F, Fanehin R, Bouchard P, et al. Scheduled administration of GnRH antagonist (Cetrorelix) on day 8 of in vitro fertilization cycles: a pilot study. Hum Reprod 1995; 10:1382-1386.
12. The Ganirelix Dose-finding Group. A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon). Hum Reprod 1998; 13:3023-3031.
13. Ragni G, Vegetti W, Baroni E, et al. Comparison of luteal phase profile in gonadotrophin stimulated cycles with or without a gonadotrophin-releasing hormone antagonist. Hum Reprod 2001; 16:2258-2262.
14. Felberbaum RE, Ludwig M, Diedrich K. Medical treatment of uterine fibroids with the LHRH antagonist: cetrorelix. Contracept Fertil Sex 1999; 27:701-709.
15. Kupker W, Felberbaum RE, Krapp M, et al. Use of GnRH antagonists in the treatment of endometriosis. Reprod Biomed Online 2002; 5:12-16.
16. Tang X, Yano T, Osuga Y, et al. Cellular mechanisms of growth inhibition of human epithelial ovarian cancer cell line by LH-releasing hormone antagonist Cetrorelix. J Clin Endocrinol Metab 2002; 8:3721-3727.
17. Emons G, Weiss S, Ortmann O, et al. LHRH might act as a negative autocrine regulator of proliferation of human ovarian cancer. Eur J Endocrinol 2000; 142:665-670.
18. Fauser BC, de Jong D, Olivennes F, et al. Endocrine profiles after triggering of final oocyte maturation with GnRH agonist after cotreatment with the GnRH antagonist ganirel during ovarian hyperstimulation for in vitro fertilization. J Clin Endocrinol Metab 2002; 87:709-715.
19. Williams S, Gibbons W, Muasher S, et al. Minimal ovarian hyperstimulation for in vitro fertilization using sequential clomiphene citrate and gonadotropin with or without the addition of a gonadotropin-releasing hormone antagonist. Fertil Steril 2002; 78:1068-1072.
20. Engel JB, Ludwig M, Felberbaum R, et al. Use of cetrorelix in combination with clomiphene citrate and gonadotrophins: a suitable approach to 'friendly IVF'? Hum Reprod 2002; 17:2022-2026.
21. Olivennes F, Alvarez S, Bouchard P, et al. The use of a new GnRH antagonist (Cetrorelix) in IVF-ET with a single dose protocol: a dose finding study of 3 versus 2 mg. Hum Reprod 1998; 13:2411-2414.
22. Albano C, Smitz J, Camus M, et al. Comparison of different doses of gonadotropin-releasing hormone antagonist Cetrorelix during controlled ovarian hyperstimulation. Fertil Steril 1997; 67:917-922.
23. Albano C, Felberbaum RE, Smitz J, et al. Ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin. Hum Reprod 2000; 15:526-531.
24. Olivennes F, Belaisch-Allart J, Emperaire JC, et al. Prospective, randomized, controlled study of in vitro fertilization-embryo transfer with a single dose of luteinizing hormone-releasing hormone (LHRH) antagonist (Cetrorelix) or a depot formula of an LHRH agonist (triprorelin). Fertil Steril 2000; 2:314-320.
25. Borm G, Mannaerts B, the European Orgalutran Study Group. Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone in effective, safe and convenient: results of a controlled, randomized, multicentre trial. Hum Reprod 2000; 15:1490-1498.
26. The North American Ganirelix Study Group. Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation. Fertil Steril 2001; 75:38-45.
27. The European and Middle East Orgalutran Study Group. Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation. Hum Reprod 2001; 16:644-651.
28. Olivennes F, Cunha-Filho JS, Fanchin R, et al. The use of GnRH antagonists in ovarian stimulation. Hum Repred Up 2002; 8:279-290. A well written review emphasizing the current treatment strategies with GnRH antagonists.
29. Tavaniotou A, Albano C, Smitz J, et al. Effect of clomiphene citrate on follicular and luteal phase luteinizing hormone concentrations in in vitro fertilization cycles stimulated with gonadotropins and gonadotropin-releasing hormone antagonist. Fertil Steril 2002; 77:733-737. Prospective randomized trial to compare the effect of clomiphene citrate on follicular and luteal phase luteinizing hormone concentrations.
30. Engel JB, Felberbaum RE, Eilers W, et al. Clomiphene-induced LH surges and cetrorelix. Reprod Biomed Online 2002; 5:109-111.
31. Hwang JL, Huang LW, Hsieh BC, et al. Ovarian stimulation by clomiphene citrate and hMG in combination with cetrorelix acetate for ICSI cycles. Hum Reprod 2003; 18:45-49.
32. Ludwig M, Katalinic A, Diedrich K. Use of GnRH antagonists in ovarian stimulation for assisted reproductive technologies compared to the long protocol. Arch Gynecol Obstet 2001; 265:175-181.
33. Al-Inany H, Aboulghar M. Gonadotrophin-releasing hormone antagonists for assisted conception [Cochrane review]. The Cochrane Library 2002; 1:1-2.
34. Tarlatzis BC, Kolibianakis M. Direct ovarian effects and safety aspects of GnRH agonists and antagonists. RBM online 2002; 5 (Suppl 1):8-13.
35. Ludwig M, Albano C, Olivennes F, et al. Plasma and follicular fluid concentrations of LHRH antagonist cetrorelix (Cetrotide) in controlled ovarian stimulation for IVF. Arch Gynecol Obstet 2002; 266:12-17.
36. Seelig AS, Al-Hasani S, Katalinic A, et al. Comparison of cryopreservation outcome with gonadotropin-releasing hormone agonists or antagonists in the collecting cycle. Fertil Steril 2002; 77:472-475.
37. Kolibianakis E, Bourgain C, Albano C et al. Effect of ovarian stimulation with recombinant follicle-stimulating hormone, gonadotropin releasing hormone antagonists, and human chorionic gonadotropin on endometrial maturation on the day of oocyte pick-up. Fertil Steril 2002; 78:1025-1029. A well written prospective study concerning the endometrium maturation in cycles with GnRH antagonists at oocyte retrieval.
38. Tavaniotou A, Albano C, Smitz J, et al. Comparison of LH concentrations in the early and mid-luteal phase in IVF cycles after treatment with HMG alone or in association with the GnRH antagonist Cetrorelix. Hum Reprod 2001; 16:663-667.
39. Albano C, Grimbizis G, Smitz J, et al. The luteal phase of non-supplemented cycles after ovarian superovulation with human menopausal gonadotropin and the gonadotropin-releasing hormone antagonist Cetrorelix. Fertil Steril 1998; 70:357-359.
40. Surrey ES, Schoooolcraft WB. Evaluating strategies for improving ovarian response of the poor responder undergoing assisted reproductive techniques. Fertil Steril 2000; 73:667-676.
41. De Placido G, Mollo A, Alviggi C, et al. Rescue of IVF cycles by HMG in pituitary down-regulated normogonadotrophic young women characterized by a poor initial response to recombinant FSH. Hum Reprod 2001; 16:1875-1879.
42. Nikolettos N, Al-Hasani S, Felberbaum R, et al. Gonadotropin-releasing hormone antagonist protocol: a novel method of ovarian stimulation in poor responders. Eur J Obstet Gynecol Reprod Biol 2001; 97:202-207.
43. Akman MA, Erden HF, Tosun SB, et al. Comparison of agonistic flare-up-protocol and antagonistic multiple dose protocol in ovarian stimulation of poor responders: results of a prospective randomized trial. Hum Reprod 2001; 16:868-870.
44. Chang PL, Zeitoun KM, Chan LK, et al. GnRH antagonist in older IVF patients: retrieval rates and clinical outcome. J Reprod Med 2002; 47:253-358.
45. Mahutte NG, Arici A. Poor responders: does the protocol make a difference? Curr Opin Obstet Gynecol 2002; 14:275-281.
46. Ludwig M, Riethmuller-Winzen H, Felberbaum RE, et al. Health of 227 children born after controlled ovarian stimulation for in vitro fertilization using the luteinizing hormone-releasing hormone antagonist cetrorelix. Fertil Steril 2001; 75:18-22.
47. Olivennes F, Mannaerts B, Struijs M, et al. Perinatal outcome of pregnancy after GnRH antagonist (ganirelix) treatment during ovarian stimulation for conventional IVF or ICSI: a preliminary report. Hum Reprod 2001; 16:1588-1591.
48. Boerrigter PJ, de Bie JJ, Mannaerts B, et al. Obstetrical and neonatal outcome after controlled ovarian stimulation for IVF using the GnRH antagonist ganirelix. Hum Reprod 2002; 17:2027-2034.
49. De Jong D, Nicholas S, Fauser BCJM. A pilot study involving minimal ovarian stimulation for in vitro fertilization: extending the 'follicle-stimulating hormone window' combined with the gonadotropin-releasing hormone antagonist cetrorelix. Fertil Steril 2000; 73:1051-1054.
50. Meldrum DR, Rivier J, Garzo G, et al. Successful pregnancies with unstimulated cycle oocyte donation using an antagonist of gonadotropin-releasing hormone. Fertil Steril 1991; 61:556-557.
51. Paulson R, Sauer MV, Lobo RA. Addition of a gonadotropin releasing hormone (GnRH) antagonist and exogenous gonadotropins to unstimulated in vitro fertilization (IVF) cycles: physiologic observations and preliminary experience. J Assist Reprod Genet 1994; 11:28-32.
52. Rongieres-Bertrand C, Olivennes F, Righini C, et al. Revival of the natural cycles in in-vitro fertilization with the use of a new gonadotrophin-releasing hormone antagonist (Cetrorelix): a pilot study with minimal stimulation. Hum Reprod 1999; 14:683-688.
53. Pelinck MJ, Hoek A, Simons AHM, et al. Efficacy of natural cycle IVF; a review of the literature. Hum Reprod Update 2002; 8:129-139.
54. Martha PM, Gray ME, Campion M, et al. Initial safety profile and hormonal dose-response characteristics of the pure GnRH antagonist, abarelix-depot, in women with endometriosis [abstract]. Gynecol Endocrinol 1999; 13 (Suppl 1):104.
55. Gonzalez-Barcena D, Alvarez RB, Ochoa ER, et al. Treatment of uterine leiomyomas with luteinizing hormone-releasing hormone antagonist cetrorelix. Hum Reprod 1997; 12:2028-2035.
56. Felberbaum RE, Ludwig M, Diedrich K. Medical treatment of uterine fibroids with the LHRH antagonist; cetrorelix. Contracept Fertil Sex 1999; 27:701-709.
57. Noci I, Coronnello M, Born P, et al. Inhibitory effect of luteinizing hormone-releasing hormone analogues on human endometrial cancer in vitro. Cancer Lett 2000; 150:71-78.
58. Roth C, Leonhardt S, Seidel C, et al. Comparative analysis of different puberty inhibiting mechanisms of two GnRH agonists and the GnRH antagonist cetrorelix using a female rat model. Pediatr Res 2000; 48:468-474.